The Condition No One Warned Her About: Angela, Granulomatous Mastitis, and a Gap We Can No Longer Ignore
It began, as these stories so often do, with a lump.
Angela — my friend, a new mother, still learning the rhythm of nights measured in feeds rather than hours found it a few months after her son was born. A hard, tender swelling in her breast, angry and red at the surface. She did what any of us would do. She assumed it was a blocked duct, then an infection. She was given antibiotics. When they didn't work, she was given more. The lump grew. The skin broke down. And somewhere in the back of every conversation sat the word no new mother should have to carry alone: cancer.
It took a biopsy to rule that out. And it took far longer to arrive at the actual answer — idiopathic granulomatous mastitis. GM. A benign, non-cancerous, but stubborn and deeply painful inflammatory disease of the breast that most people, including many clinicians, have simply never heard of.
Angela had never heard of it. Neither, in that moment, had most of the people around her. What she remembers most is not the pain, though there was a great deal of it. It is the feeling of being lost inside a system that had no clear map for what was happening to her body.
A condition that is quietly becoming less rare
Granulomatous mastitis was first described in 1972. For decades it was treated as a curiosity — vanishingly rare, seen perhaps once in a career. But I am hearing about it more and more. From friends. From patients. From women writing to me privately because they have nowhere else to turn.
It typically appears in women of reproductive age, often within a few years of pregnancy or breastfeeding. It disproportionately affects women of South Asian, Middle Eastern, Hispanic, and African heritage — which means it lands hardest on exactly the populations our research and our clinical pathways have historically served least well. It mimics inflammatory breast cancer so closely that diagnosis is one of exclusion, arrived at only after imaging, biopsy, and a great deal of anxiety. And it recurs. Women describe cycles of flare, treatment, remission, and relapse that stretch across years.
Here is what troubles me most as a doctor. We still do not fully understand what causes it. Two theories dominate — that it is an organ-specific autoimmune condition, and that it is driven by hard-to-culture bacteria, particularly Corynebacterium species. Both may be true in different women. But the honest position is that the science is thin. As of the end of 2025, only around eighteen clinical trials worldwide had ever specifically addressed this disease, clustered in a handful of countries. There is no dedicated pipeline. No orphan programme. No company that has planted a flag and said: this one is ours to solve.
In the UK, the pathway is years old
I want to be direct about the situation here at home, because it is part of why I am writing this.
In the UK, when a woman is finally diagnosed with GM, the treatment she is offered is systemic steroids — steroids that circulate through the whole body, with all the side effects that implies, taken over long and repeated courses. There is no established intralesional pathway, no standard of targeted local therapy of the kind being trialled elsewhere. Women move between antibiotics, systemic steroids, surgery, and prolonged monitoring, often without a clear roadmap, often repeating the same steps a second and third time when the disease returns. The pathway is old. It has not kept pace with what we are learning. And the women living through it deserve better than a protocol that has barely changed in a generation.
Angela recovered, in time. Many women do. But "in time" can mean two years of pain, disfigurement, fear, and the exhausting work of being your own advocate inside a system that keeps handing you the same three tools.
Where innovation could change the story
I have been researching innovators whose technologies could have meaningful relevance to the GM space — not because any of them is working on this condition today, but because the capabilities they have built are precisely what this disease needs:
- iSono Health — automated 3D breast ultrasound and longitudinal monitoring
- Koios Medical — AI-supported breast-ultrasound interpretation
- Aiosyn — AI and digital pathology for breast tissue analysis
- Karius — advanced microbial and pathogen detection
- Noscendo / Bruker — metagenomic diagnostics for difficult-to-detect pathogens
Put these capabilities together and you begin to see a much better future for granulomatous mastitis: earlier and more confident diagnosis, better identification of Corynebacterium-associated disease, more consistent imaging, clearer pathology, more personalised treatment, and proper recurrence monitoring so women are no longer navigating relapse blind.
None of this is science fiction. Every piece already exists. What is missing is someone willing to assemble it around this specific, underserved, and growing need.
An open invitation
So this is a call — and a genuine one.
I would love to connect with founders, clinicians, researchers, diagnostic companies, AI innovators, patient advocates, and women's-health investors interested in advancing this space. And I want to be explicit: I would be very happy to invest in, advise, or actively support a startup building solutions for granulomatous mastitis.
There is real opportunity here to create better tools, stronger evidence, and more coordinated care pathways for the women living with GM — women like Angela, who deserved a map from the very beginning.
Please share this post for visibility. The right innovator may already be working on an important part of this puzzle. Let's find them.
#GranulomatousMastitis #WomensHealth #BreastHealth #FemTech #Diagnostics #DigitalHealth #HealthInnovation